Latest United States News

Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.

RMA Global grew revenue 7% to $22.7 million in FY26, driven by US market gains and integration of Curated Social, but losses widened to $3.5 million. The company rebranded as Renowned and secured record US brokerage deals.

Haranga Resources appoints seasoned mining executive Patrick Mutz as Managing Director and CEO, aiming to accelerate development of its high-grade Lincoln Gold Project in California.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Peak Processing Limited’s FY26 results reveal a doubling loss from continuing operations to $10 million amid a $4.35 million impairment, offset partially by a $2.5 million profit from discontinued operations. The company completed an operational reset and posted its first positive EBITDA quarter in June 2026.

L1 Gold Fund Limited (ASX:LGF) has launched a retail entitlement offer aiming to raise up to $261.7 million by issuing one new share for every three held, priced at $2.25 each. This follows a $254.9 million institutional placement and entitlement offer completed earlier in August.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.